BioCardia (NASDAQ:BCDA) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of BioCardia (NASDAQ:BCDA) in a research report released on Thursday morning,Benzinga reports. They currently have a $25.00 target price on the stock.

BioCardia Trading Down 4.0 %

BioCardia stock traded down $0.08 during trading on Thursday, reaching $1.94. The company had a trading volume of 46,558 shares, compared to its average volume of 297,191. The firm’s 50-day simple moving average is $2.59 and its 200 day simple moving average is $3.36. BioCardia has a 52 week low of $1.91 and a 52 week high of $14.40. The firm has a market capitalization of $4.12 million, a price-to-earnings ratio of -0.48 and a beta of 1.28.

BioCardia (NASDAQ:BCDA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.78). On average, analysts predict that BioCardia will post -5.06 earnings per share for the current year.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.